Do analysts prefer WEED or MJN?

Canopy Growth presently has a consensus price target of C$1.88, indicating a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities analysts plainly believe Canopy Growth is more favorable than Cronos Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, WEED or MJN?

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$284.60M 2.11 -C$1.05B -C$0.88 N/A Cronos Group N/A N/A N/A N/A N/A

Do analysts prefer WEED or CMED?

Canopy Growth presently has a consensus target price of C$1.88, suggesting a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Canopy Growth is more favorable than CanniMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, WEED or CMED?

CanniMed Therapeutics has lower revenue, but higher earnings than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$284.60M 2.11 -C$1.05B -C$0.88 N/A CanniMed Therapeutics N/A N/A N/A N/A N/A

Do analysts recommend EMC or WEED?

Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Emblem. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emblem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable valuation & earnings, EMC or WEED?

Emblem has higher earnings, but lower revenue than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Emblem $5.71M 43.02 -$24.81M -$0.19 N/A Canopy Growth C$284.60M 2.11 -C$1.05B -C$0.88 N/A

Do analysts recommend ICC or WEED?

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Canopy Growth is more favorable than ICC Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ICC Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable earnings & valuation, ICC or WEED?

ICC Labs has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ICC Labs C$533.68K 419.04 C$2.35M C$0.02 95.29 Canopy Growth C$284.60M 2.11 -C$1.05B -C$0.88 N/A

Which has better earnings & valuation, OGI or WEED?

Organigram has higher earnings, but lower revenue than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$274.19M 0.74 -C$57.23M -C$0.21 N/A Canopy Growth C$284.60M 2.11 -C$1.05B -C$0.88 N/A

Canopy Growth (WEED) Competitors

C$1.42 -0.01 (-0.70%)

As of 07/3/2026 04:00 PM Eastern

Compare

WEED vs. MJN, CMED, EMC, ICC, and OGI

Should you buy Canopy Growth stock or one of its competitors? MarketBeat compares Canopy Growth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Canopy Growth include Cronos Group (MJN), CanniMed Therapeutics (CMED), Emblem (EMC), ICC Labs (ICC), and Organigram (OGI). These companies are all part of the "cannabis" industry.

How does Canopy Growth compare to Cronos Group?

Canopy Growth (TSE:WEED) and Cronos Group (CVE:MJN) are both small-cap cannabis companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Cronos Group has lower revenue, but higher earnings than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$284.60M	2.11	-C$1.05B	-C$0.88	N/A
Cronos Group	N/A	N/A	N/A	N/A	N/A

Cronos Group has a net margin of 0.00% compared to Canopy Growth's net margin of -84.76%. Cronos Group's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-84.76%	-35.48%	-3.83%
Cronos Group	N/A	N/A	N/A

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cronos Group had 1 more articles in the media than Canopy Growth. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Canopy Growth. Cronos Group's average media sentiment score of 0.74 beat Canopy Growth's score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Canopy Growth	Neutral
Cronos Group	Positive

Canopy Growth presently has a consensus price target of C$1.88, indicating a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities analysts plainly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Canopy Growth beats Cronos Group on 6 of the 11 factors compared between the two stocks.

How does Canopy Growth compare to CanniMed Therapeutics?

Canopy Growth (TSE:WEED) and CanniMed Therapeutics (TSE:CMED) are both small-cap cannabis companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

CanniMed Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -84.76%. CanniMed Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-84.76%	-35.48%	-3.83%
CanniMed Therapeutics	N/A	N/A	N/A

4.3% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CanniMed Therapeutics has lower revenue, but higher earnings than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$284.60M	2.11	-C$1.05B	-C$0.88	N/A
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Canopy Growth's average media sentiment score of 0.00 equaled CanniMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Canopy Growth	Neutral
CanniMed Therapeutics	Neutral

Canopy Growth presently has a consensus target price of C$1.88, suggesting a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Canopy Growth is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Canopy Growth beats CanniMed Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Canopy Growth compare to Emblem?

Emblem (CVE:EMC) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Emblem has higher earnings, but lower revenue than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emblem	$5.71M	43.02	-$24.81M	-$0.19	N/A
Canopy Growth	C$284.60M	2.11	-C$1.05B	-C$0.88	N/A

In the previous week, Emblem had 1 more articles in the media than Canopy Growth. MarketBeat recorded 1 mentions for Emblem and 0 mentions for Canopy Growth. Emblem's average media sentiment score of 0.67 beat Canopy Growth's score of 0.00 indicating that Emblem is being referred to more favorably in the media.

Company	Overall Sentiment
Emblem	Positive
Canopy Growth	Neutral

Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Emblem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emblem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

4.3% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Emblem has a net margin of 0.00% compared to Canopy Growth's net margin of -84.76%. Emblem's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emblem	N/A	N/A	N/A
Canopy Growth	-84.76%	-35.48%	-3.83%

Summary

Emblem beats Canopy Growth on 8 of the 15 factors compared between the two stocks.

How does Canopy Growth compare to ICC Labs?

ICC Labs (CVE:ICC) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 32.04%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Canopy Growth is more favorable than ICC Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICC Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ICC Labs' average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score.

Company	Overall Sentiment
ICC Labs	Neutral
Canopy Growth	Neutral

ICC Labs has a net margin of 0.00% compared to Canopy Growth's net margin of -84.76%. ICC Labs' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICC Labs	N/A	N/A	N/A
Canopy Growth	-84.76%	-35.48%	-3.83%

ICC Labs has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICC Labs	C$533.68K	419.04	C$2.35M	C$0.02	95.29
Canopy Growth	C$284.60M	2.11	-C$1.05B	-C$0.88	N/A

Summary

ICC Labs beats Canopy Growth on 7 of the 13 factors compared between the two stocks.

How does Canopy Growth compare to Organigram?

Organigram (TSE:OGI) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Organigram presently has a consensus price target of C$3.13, indicating a potential upside of 115.52%. Canopy Growth has a consensus price target of C$1.88, indicating a potential upside of 32.04%. Given Organigram's stronger consensus rating and higher possible upside, equities analysts plainly believe Organigram is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Organigram has a net margin of -9.19% compared to Canopy Growth's net margin of -84.76%. Organigram's return on equity of -6.83% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	-9.19%	-6.83%	-5.56%
Canopy Growth	-84.76%	-35.48%	-3.83%

Organigram has a beta of 1.449406, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.44612, indicating that its stock price is 45% more volatile than the broader market.

4.0% of Organigram shares are held by institutional investors. Comparatively, 4.3% of Canopy Growth shares are held by institutional investors. 31.3% of Organigram shares are held by company insiders. Comparatively, 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Organigram has higher earnings, but lower revenue than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$274.19M	0.74	-C$57.23M	-C$0.21	N/A
Canopy Growth	C$284.60M	2.11	-C$1.05B	-C$0.88	N/A

In the previous week, Organigram's average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score.

Company	Overall Sentiment
Organigram	Neutral
Canopy Growth	Neutral

Summary

Organigram beats Canopy Growth on 8 of the 13 factors compared between the two stocks.

Get Canopy Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WEED vs. The Competition

Export

Metric	Canopy Growth	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$603.68M	C$6.60B	C$7.18B	C$13.07B
Dividend Yield	4.80%	2.83%	2.67%	6.18%
P/E Ratio	-1.61	5.11	28.02	36.51
Price / Sales	2.11	1,653.39	534.82	10.34
Price / Cash	1.63	10.18	49.26	82.29
Price / Book	0.70	10.83	10.96	4.52
Net Income	-C$1.05B	C$20.27B	C$3.57B	C$299.09M
7 Day Performance	7.58%	1.30%	2.12%	1.85%
1 Month Performance	-1.39%	-1.17%	5.25%	1.71%
1 Year Performance	-19.32%	9.82%	33.29%	36.40%

Canopy Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WEED Canopy Growth	N/A	C$1.42 -0.7%	C$1.88 +32.0%	-19.3%	C$603.68M	C$284.60M	N/A	2,700
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600	News Coverage
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
EMC Emblem	N/A	$1.88 +1.6%	N/A	+0.0%	$245.45M	$5.71M	N/A	N/A	News Coverage
ICC ICC Labs	N/A	C$1.62 -5.8%	N/A	+0.0%	C$223.64M	C$533.68K	95.29	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:WEED) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Canopy Growth (WEED) Competitors

WEED vs. MJN, CMED, EMC, ICC, and OGI

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to CanniMed Therapeutics?

Summary

How does Canopy Growth compare to Emblem?

Summary

How does Canopy Growth compare to ICC Labs?

Summary

How does Canopy Growth compare to Organigram?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Canopy Growth (WEED) Competitors

WEED vs. MJN, CMED, EMC, ICC, and OGI

How does Canopy Growth compare to Cronos Group?

Which has preferable valuation and earnings, WEED or MJN?

Is WEED or MJN more profitable?

Do insiders & institutionals believe in WEED or MJN?

Does the media refer more to WEED or MJN?

Do analysts prefer WEED or MJN?

Summary

How does Canopy Growth compare to CanniMed Therapeutics?

Is WEED or CMED more profitable?

Do institutionals & insiders hold more shares of WEED or CMED?

Which has better valuation and earnings, WEED or CMED?

Does the media refer more to WEED or CMED?

Do analysts prefer WEED or CMED?

Summary

How does Canopy Growth compare to Emblem?

Which has preferable valuation & earnings, EMC or WEED?

Does the media favor EMC or WEED?

Do analysts recommend EMC or WEED?

Do institutionals and insiders have more ownership in EMC or WEED?

Is EMC or WEED more profitable?

Summary

How does Canopy Growth compare to ICC Labs?

Do analysts recommend ICC or WEED?

Do institutionals & insiders hold more shares of ICC or WEED?

Does the media favor ICC or WEED?

Is ICC or WEED more profitable?

Which has preferable earnings & valuation, ICC or WEED?

Summary

How does Canopy Growth compare to Organigram?

Do analysts prefer OGI or WEED?

Is OGI or WEED more profitable?

Which has more volatility and risk, OGI or WEED?

Do insiders and institutionals believe in OGI or WEED?

Which has better earnings & valuation, OGI or WEED?

Does the media refer more to OGI or WEED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools